Ticker Symbol: PRFX
PainReform Ltd
$2.29 - 02-12-2024 4 p.m. ET
Exchange: NASDAQ
Currency:
USD
Asset
Type: Common Stock
CIK:0001801834
Company Profile
PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: www.painreform.com
CEO: N/A
Tags:
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Medicinal and Botanical Manufacturing
Pricing
Last Updated: October 13, 2023 03:00 PM EST
Previous Close: $2.52
Change:
-$0.21
(
-7.69%)
Days Range: $2.52 - $2.76
Beta: -
52wk. High: $26.41
52wk. Low: $2.29
Ytd. Change -41.54%
50 Day Moving Average: $3.44
200 Day Moving Average: $5.36
Shares Outstanding: 1558348
Valuation
Market Cap: 392.7M
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A